FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

PERSPECTIVE ROUNDTABLE Previous Volume 360:e18 March 26, 2009 Number 13 Next

PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Andriole, G. L. Related Article by Schröder, F. H. PubMed Citation

In two large randomized trials, researchers examined the effect of annual prostate-specific–antigen (PSA) screening on the rate of death from prostate cancer and found that it was small and was offset by false positive diagnoses. Since screening may have benefits in catching cancers early but may also carry risks including that of unnecessary treatment, professional societies have split on the question of whether to recommend regular PSA screening. In a roundtable discussion moderated by Dr. Thomas Lee, oncologist Philip Kantoff and primary care physician Mary McNaughton-Collins debate the clinical implications of the new findings and the best way to advise patients about undergoing PSA testing. Should these studies change practice? Watch the video, participate in the poll, and contribute your thoughts at NEJM.org.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.